Clinical Trial: Study of REN-1654 in Patients with Sciatica Pain

This study is currently recruiting patients.

Sponsored by: Renovis
Information provided by: Renovis

Purpose

The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with pain that radiates down the leg(s), and is typical of sciatica (lumbosacral radiculopathy). These patients will usually have a herniated disc that is causing compression on the nerves coming out of the spinal column.

Condition Treatment or Intervention Phase
Sciatica
Herniated Disc
Radiculopathy
 Drug: REN-1654
Phase II

MedlinePlus related topics:  Herniated Disk;   Peripheral Nerve Disorders;   Sciatica

Study Type: Interventional
Study Design: Educational/Counseling/Training, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title: REN-1654 in Sciatica: A Phase 2, Randomized, Double-blind, Placebo controlled, Multi-center Study in Subjects with Pain due to Lumbosacral Radiculopathy

Further Study Details: 
Primary Outcomes: Leg Pain: Change in Average Daily 11-Point Categorical Pain Intensity Rating at the end of the 3-week treatment period
Secondary Outcomes: Initiation of the following clinical interventions and time to intervention, if elected, through the 3-week treatment period and 3-week post treatment follow-up period:; [1] Local, regional, or spinal (articular, epidural, intrathecal, or nerve root block) injections of medications for pain treatment. [2] Surgery for treatment of sciatica symptoms; Use of concomitant analgesic medications (tracked by daily log of medication usage); Back Pain: Change in Average Daily Categorical Pain Intensity; Leg Pain: Change in Maximum (or movement-induced) Daily Categorical Pain Intensity Rating; Back Pain: Change in Maximum (or movement-induced) Daily Categorical Pain Intensity; Change in Oswestry Low Back Disability Questionnaire; Change in Straight Leg Raising test; Change in muscle weakness; Change in sensory deficit; Change in tendon reflexes; Global impression of change: subject and investigator
Expected Total Enrollment:  72

Study start: December 2003;  Expected completion: September 2005
Last follow-up: April 2005;  Data entry closure: June 2005

This is a multi-center, randomized, double-blind, placebo-controlled study to determine the efficacy and tolerability of REN-1654 in subjects with sciatica. After screening and baseline clinical assessments, subjects will be randomly assigned to receive REN 1654 100 mg or matching placebo, once daily for 3 weeks. Leg pain, back pain and other efficacy measures will be assessed at 1 and 3 weeks after initiation of treatment. A subset of patients will undergo analysis of blood levels of REN-1654 during the course of the study (pharmacokinetics). Subjects will discontinue treatment after 3 weeks and return after a further 3 weeks off therapy for a final clinical assessment 6 weeks after initiation of treatment. If a subject does not return for follow-up, an effort will be made by telephone to document their clinical status and whether other interventions have been made.

Eligibility

Ages Eligible for Study:  18 Years   -   55 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

  • Males or females, ages 18 to 55, able and willing to provide written informed consent to participate in the study.
  • Able to read, understand and follow the study instructions, including completion of pain intensity rating scales.
  • Leg pain radiating to or below the knee in a dermatomal pattern, diagnosed as being due to sciatica or lumbar or lumbosacral radiculopathy, the onset of which occurred 2 to 12 weeks prior to initiation of study treatment.
  • Leg pain severity on a screening Categorical Pain Intensity Rating (for the prior 24 hour period) of at least 4, using an 11-point categorical pain intensity scale with 0 = no pain and 10 = worst pain imaginable.
  • Leg pain on a screening Categorical Pain Intensity Rating rated as more severe than back pain.
  • Positive straight leg raising (SLR) test as defined in Appendix B of this protocol.
  • Subjects who are compliant in maintaining a Pain Diary between screening and baseline visits, and who record a 24-hour average Categorical Pain Intensity Rating score of at least 4 or greater on at least 3 days during the week prior to baseline visit.
  • Subject who can maintain stable pharmacologic treatments for sciatica symptoms taken prior to dosing including analgesics, anti-inflammatory medications (e.g. NSAIDS), antidepressants, anticonvulsants, anxiolytics, or muscle relaxants. Subjects must be on stable doses of such medications for 2 weeks prior to the baseline visit, and maintained on the same doses throughout the study. Medications taken on an as-needed basis are permitted, and subjects will be asked to record daily usage of such medications in the subject diary.
  • Subjects who at screening are receiving adjunctive analgesic therapy such as acupuncture or biofeedback should either discontinue it or establish a schedule of treatments that will remain consistent for 2 weeks prior to the baseline visit, and throughout the study.
  • Subject with screening laboratory values within normal limits, or if abnormal must be considered not clinically significant and in the opinion of the Investigator not to place the subjects at risk.
  • If female, must be post-menopausal, surgically sterile, not currently pregnant (verified by a screening pregnancy test) or nursing, and using a reliable contraception method such as intrauterine device (IUD), hormonal birth control pills, or double barrier method (male condom, female condom or diaphragm with spermicidal jelly).
  • If male, must agree to use double-barrier methods of contraception.

Exclusion Criteria:

  • History of peripheral neuropathy or any other pain conditions with pain intensity equal to or greater than the pain associated with sciatica.
  • Motor loss in a muscle corresponding to the affected dermatome graded as more than “trace”.
  • History of cauda equina syndrome, symptomatic scoliosis, spondylolisthesis (degenerative or isthmic), ankylosing spondylitis, rheumatoid arthritis or other inflammatory arthropathies. Degenerative arthritis is allowed.
  • History of hepatic, cardiovascular, renal, gastrointestinal, hematological, neurological, endocrine (including diabetes), metabolic, pulmonary, immunological (including HIV infection) or psychiatric disease that in the opinion of the Investigator would pose a significant safety risk for a subject exposed to an investigational compound such as REN-1654.
  • History of the following ophthalmic disorders based upon general medical review at the screening visit. Subjects will further undergo a screening ophthalmologic assessment. Should any of the following be identified at the screening ophthalmologic examination, the subject will be excluded from the study. *Symptomatic cataract, resulting in any visual impairment (if a subject has been diagnosed with cataract to a degree that the cataract interferes with daily living and/or regarding which an ophthalmologist has recommended cataract surgery); *Other vision-impairing disorders (if a subject is aware of any eye disorder that has impaired vision, such as age-related macular degeneration, lazy eye (amblyopia), double vision, or any optic nerve inflammation; presbyopia and other non-pathological visual acuity deficits are not exclusionary); *Glaucoma or history of ocular hypertension (intraocular pressures greater than 21 mmHg).
  • Cognitive or psychiatric disorders that may diminish compliance with study procedures, including maintenance of a daily pain diary and accurate dosing of study medication.
  • Subjects who, at time of enrollment, have requested for or been advised by their physicians to receive local, regional, or spinal (articular, epidural, intrathecal or nerve root block) injections of medications for pain treatment or surgical intervention for their sciatica symptoms.
  • Although subjects who report work-related injuries will be allowed to enroll, subjects will be excluded if they are involved in litigation related to the current episode of sciatica.
  • Subjects with a screening creatinine laboratory value of ≥ 2.0 mg/dL.
  • Screening liver enzyme results greater than the upper limit of the normal range
  • Use of chemotherapy agents or history of cancer, other than basal cell carcinoma and squamous cell carcinoma, within five years prior to the screening visit.
  • History of drug or alcohol abuse within one year prior to screening.
  • Use within 2 weeks before start of study investigational compound dosing at baseline and through the end of the study of any investigational compound, any epidural, intrathecal, or nerve root block agent, corticosteroids, etanercept or other anti-TNF-α agent, topical anesthetics, or topical analgesics .
  • Previous participation in another REN-1654 study.

Location and Contact Information

Randall W Moreadith, MD, PhD      650-266-1531    rmoreadith@renovis.com
William K Schmidt, PhD      650-266-1534    wschmidt@renovis.com

Alabama
      Alabama Clinical Therapeutics, Birmingham,  Alabama,  35235,  United States; Recruiting

Arizona
      Advanced Clinical Therapeutics, LLC, TUSCON,  Arizona,  85712,  United States; Recruiting

California
      Orthopaedic Spine Center at Stanford University Medical Center, Stanford,  California,  94305,  United States; Recruiting

Colorado
      Mile High Research Center, Denver,  Colorado,  80218,  United States; Recruiting

Florida
      Clinical Research of West Florida, Clearwater,  Florida,  33765,  United States; Recruiting

      Renstar Medical Research, Inc., Ocala,  Florida,  34471,  United States; Recruiting

      Suncoast Neuroscience Associates, St. Petersburg,  Florida,  33701,  United States; Recruiting

Georgia
      Emory Orthopaedics and Spine Center, Atlanta,  Georgia,  30329,  United States; Recruiting

Massachusetts
      Brigham & Women's Hospital, Pain Trials Center, Boston,  Massachusetts,  02115,  United States; Recruiting

Missouri
      A&A Pain Institute of St. Louis, St. Louis,  Missouri,  63141,  United States; Recruiting

      Washington University School of Medicine, Pain Management Center, St. Louis,  Missouri,  63110,  United States; Recruiting

New York
      Research Across America, New York,  New York,  10022,  United States; Recruiting

North Carolina
      Asheville Neurology Specialists, PA, Asheville,  North Carolina,  28806,  United States; Recruiting

      Wake Research Associates, Raleigh,  North Carolina,  27612,  United States; Recruiting

Ohio
      The Cleveland Clinic Spine Institute, Cleveland,  Ohio,  44195,  United States; Recruiting

Pennsylvania
      Lehigh Valley Hospital Neurosciences and Pain Research, Allentown,  Pennsylvania,  18103,  United States; Recruiting

Rhode Island
      Omega Medical Research, Warwick,  Rhode Island,  02886,  United States; Recruiting

Texas
      Central Texas Spine Institute, Austin,  Texas,  78731,  United States; Recruiting

Utah
      Advanced Clinical Research, West Jordan,  Utah,  84088,  United States; Recruiting

Study chairs or principal investigators

Randall W Moreadith, MD, PhD,  Study Director,  Chief Medical Officer, Renovis, Inc.   

More Information

Publications

Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001 Jun;6(2):67-72.

Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllonen E, Lindgren KA, Rantanen P, Tervonen O, Niinimaki J, Seitsalo S, Hurri H. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine. 2003 Apr 15;28(8):750-3; discussion 753-4.

Study ID Numbers:  REN-1654-2-03
Record last reviewed:  April 2005
Last Updated:  April 5, 2005
Record first received:  April 4, 2005
ClinicalTrials.gov Identifier:  NCT00107055
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources